

Dear Editors and Reviewers:

I appreciate the time and effort you have dedicated to providing your valuable feedback on my manuscript named "Papillary Thyroid Carcinoma Occurring with Undifferentiated Pleomorphic Sarcoma: A Case Report and Literature Review". I am grateful for the insightful comments on my paper. I have been able to incorporate changes to reflect most of the suggestions provided by you and have highlighted the changes within the manuscript.

Here is a point-by-point response to the reviewers' comments and concerns.

Comments from Reviewer 1

- ◆ **Comment 1:** "Discussion section" is too long

Response: Thank you very much for your comment. The discussion part was shortened by deleting unimportant information.

- ◆ **Comment 2:** The authors wrote "Riti described", or "Nicola report". In normal, the last name of the investigator cited must be used, and Nikola must be replaced by Nikola et al.

Response: I am very sorry for my incorrect writing. The description of the author's name was modified as Aggarwal et al (Page 7/ Line 26) and Nicola et al (Page 8/ Line 1).

- ◆ **Comment 3:** I think Figure 7 is unnecessary.

Response: Thank you for pointing this out. Figure 7 was deleted as suggested.

Comments from Reviewer 2

- ◆ **Comment 1:** Which malignancy is first, PTC or UPS?

Response: Thank you very much for your comment. Due to the late discovery of the disease, this patient's first pathological findings suggested both PTC and UPS, so we could not tell which tumor appeared first. Regarding your consideration, I had added an explanation of this situation in the second paragraph of "Discussion". (Page 8/ Line8-9)

- ◆ **Comment 2:** Please provide details of the lung lesions.

Response: Thank you for pointing this out. Details of the lung metastasis, including the discovery time, symptoms (Page 7/ Line 2-3), and the specific size and distribution of the nodules (Page 16/ Line 27-29) were added as suggested.

- ◆ **Comment 3:** Have you done genetic testing ?

Response: Yes, the result of the genetic testing is in page 6/ line5-9. Gene mutation analysis was performed using a thyroid cancer 8 gene detection kit (fluorescent PCR), which detects oncogenic mutations (BRAF, NRAS, HRAS,

KRAS, and TERT) and chromosome rearrangements (CCDC6-RET, PAX8/PPAR, and EVT6-NTRK3). The patient had BRAF and TERT mutations.

Hope our article could be accepted and published in the *World Journal of Clinical Cases* soon. If reviewers and editors have any questions, please don't hesitate to let me know. Thank you.

Best wishes,

Yu-Li Lee